Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells

Cytokines, Cellular and Molecular Therapy

Volumn 7, Issue 4, 2002, Pages 135-142

  Liebau, Christian ^a   Merk, Harry ^a   Schmidt, Sebastian ^c   Roesel, Christian ^b   Karreman, Christiaan ^b   Prisack, Johannes Bernd ^b   Bojar, Hans ^b   Baltzer, Axel W A ^c  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Centre for Molecular Orthopaedics   (Germany)

Author keywords

Experimental study; ICAM 1; IL 12; IL 18; NK cells; Osteosarcoma

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERFERON ANTIBODY; PROPIDIUM IODIDE; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CONTROLLED STUDY; CYTOLYSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE; NATURAL KILLER CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

CELL LINE, TUMOR; COCULTURE TECHNIQUES; FLOW CYTOMETRY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-18; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; OSTEOSARCOMA; PROPIDIUM; UP-REGULATION;

EID: 0346780705     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: 10.1080/13684730310001977     Document Type: Article

References (29)

1. Rhim JS, Cho HY, Huebner RJ, Non-producer human cells induced by murine sarcoma virus. Int J Cancer (1975) 15: 23-9.
2. Fogh J, Fogh JM, Orfeo T, One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst (1977) 59: 221-6.
3. Billiau A, Edy VG, Heremans H et al, Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother (1977) 12: 11-5.
4. Ponten J, Saksela E, Two established in vitro cell lines from human mesenchymal tumours. Int J Cancer (1967) 2: 434-47.
5. Scotlandi K, Baldini N, Campanacci M et al, Induction of HLA class II antigens in osteosarcoma cells by interferons and tumor necrosis factor alpha. Anticancer Res (1992) 12: 767-72.
6. Mariani E, Tarozzi A, Meneghetti A et al, Human osteosarcoma cell susceptibility to natural killer cell lysis depends on CD54 and increases after TNF alpha incubation. FEBS Lett (1997) 406: 83-8.
7. Lehmann C, Glass B, Zeis M et al, Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity. Cancer Immunol Immunother (1999) 48: 209-13.
8. Podack ER, Hengartner H, Lichtenheld MG, A central role of perforin in cytolysis? Annu Rev Immunol (1991) 9: 129-57.
9. Henkart PA, Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity (1994) 1: 343-6.
10. D'Andrea A, Rengaraju M, Valiante NM et al, Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med (1992) 176: 1387-98.
11. Chan SH, Perussia B, Gupta JW et al, Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 173: 869-79.
12. Kobayashi M, Fitz L, Ryan M et al, Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med (1989) 170: 827-45.
13. Ushio S, Namba M, Okura T et al, Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol (1996) 156: 4274-9.
14. Micallef MJ, Ohtsuki T, Kohno K et al, Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol (1996) 26: 1647-51.
15. Lauwerys BR, Renauld JC, Houssiau FA, Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine (1999) 11: 822-30.
16. Yoshimoto T, Takeda K, Tanaka T et al, IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol (1998) 161: 3400-7.
17. Coughlin CM, Salhany KE, Wysocka M et al, Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest (1998) 101: 1441-52.
18. Yamanaka K, Hara I, Nagai H et al, Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol Immunother (1999) 48: 297-302.
19. Rodella L, Rezzani R, Zauli G et al, Apoptosis induced by NK cells is modulated by the NK-active cytokines IL-2 and IL-12. Int Immunol (1998) 10: 719-25.
20. Hogg N, Landis RC, Adhesion molecules in cell interactions. Curr Opin Immunol (1993) 5: 383-90.
21. Kohka H, Yoshino T, Iwagaki H et al, Interleukin-18/interferon-gamma-inducing factor, a novel cytokine, up-regulates ICAM-1 (CD54) expression in KG-1 cells. J Leukoc Biol (1998) 64: 519-27.
22. Brunda MJ, Luistro L, Hendrzak JA et al, Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol (1995) 17: 71-7.
23. Nastala CL, Edington HD, McKinney TG et al, Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 153: 1697-706.
24. Zitvogel L, Tahara H, Robbins PD et al, Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol (1995) 155: 1393-403.
25. Wigginton JM, Komschlies KL, Back TC et al, Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst (1996) 88: 38-43.
26. Benacerraf B, Role of MHC gene products in immune regulation. Science (1981) 212: 1229-38.
27. Tanaka K, Yoshioka T, Bieberich C, Jay G, Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol (1988) 6: 359-80.
28. Bernards HJ, Suppression of MHC gene expression in cancer cells. Trends Genetics (1987) 3: 298-301.
29. Bontkes HJ, Walboomers JM, Meijer CJ et al, Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet (1998) 351: 187-8.